Ladiratuzumab vedotin (anti-SLC39A6) - Primary antibody, specific to SLC39A6, >90% (SDS-PAGE&SEC), Human IgG1, INHIBITOR of Tubulin inhibitor, INHIBITOR of Tubulin inhibitor
Ladiratuzumab vedotin (anti-SLC39A6) - Primary antibody, specific to SLC39A6, >90% (SDS-PAGE&SEC), Human IgG1, INHIBITOR of Tubulin inhibitor, INHIBITOR of Tubulin inhibitor
GRADE & PURITYAnimal Free?Animal-free — produced without animal-derived components to reduce contamination risk. Use in biomanufacturing and culture avoiding animal-origin material.Carrier Free?Carrier-free — supplied without added carrier protein/stabilizer. Use when carriers (e.g. BSA) would interfere with conjugation or sensitive assays.Recombinant?Recombinant — produced via recombinant expression for defined sequence and consistency. Use for reproducible, animal-free proteins of known origin.Validated?Validated grade — performance confirmed in defined applications before release. Use when you want documented assurance the reagent works as stated.ExactAb™?ExactAb™ — Aladdin's antibody line emphasizing precision and validated quality. Use for reliable, specificity-validated antibody applications.Low Endotoxin?Low-endotoxin grade — endotoxin reduced to low controlled levels. Use in sensitive biological work where high endotoxin would interfere.Azide Free?Azide-free — without sodium azide preservative. Use in conjugations, cell work, or assays where azide is toxic or inhibitory.≥90%(SDS-PAGE&SEC-HPLC)See COA
Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥90%(SDS-PAGE&SEC-HPLC), See COA Animal Free,Azide Free,Carrier Free,ExactAb™,Low Endotoxin,Recombinant,Validated for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
🌡
Storage & shipping
Store at -80°C,Avoid repeated freezing and thawing Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
📋
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
📚
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Descripción general
Ladiratuzumab vedotin (anti-SLC39A6) is an antibody-drug conjugate (ADC) composed of humanized anti-LIV-1 antibody, conjugated to Monomethyl auristatin E (MMAE), via a proteolytically cleavable type linker. Ladiratuzumab vedotin (anti-SLC39A6) has the potential for use in multiple carcinomas. Purity >90% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg
Specifications
Product Name
Ladiratuzumab vedotin (anti-SLC39A6) - Primary antibody, specific to SLC39A6, >90% (SDS-PAGE&SEC), Human IgG1, INHIBITOR of Tubulin inhibitor
Sinónimos
Estrogen regulated protein LIV 1 6 antibody | Estrogen-regulated protein LIV-1 antibody | LIV 1 antibody | LIV 1 protein, estrogen regulated antibody | S39A6_HUMAN antibody | SLC39A6 antibody | Solute carrier family 39 (metal ion transporter), member 6 an
Especificaciones y pureza
Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥90%(SDS-PAGE&SEC-HPLC), See COA
Store at -80°C,Avoid repeated freezing and thawing
Enviado en
Dry ice packs + Cold packs
Estabilidad y almacenamiento
Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.
Imágenes
Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) - Flow Cytometry Flow Cytometry analysis of Jurkat cells labelling SLC39A6 (red) with Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) at 1.0 μg/mL for 1 hour at 4°C. Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) - Flow Cytometry Flow Cytometry analysis of ZDFH001-human-LIV1 A6-C2203027 cells at 1×105 cell/well can bind Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) with the EC₅₀ of 80.0 ng/mL.
Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) - SEC The purity of Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) is more than 95% verified by HPLC.
Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) - ELISA Immobilized Recombinant Human SLC39A6/LIV-1 Protein (rp176717) at 1.0 μg/mL can bind Ladiratuzumab vedotin (anti-SLC39A6) (Ab183329) with the EC₅₀ of 18.4 ng/mL.
Documentation
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
We use cookies to ensure the website functions properly and, where permitted, to improve your experience. You can manage your preferences at any time in Settings. Learn more in our Cookie Policy.
Shall we send you a message when we have discounts available?
Remind me later
Thank you! Please check your email inbox to confirm.
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
ZJ24F0910906